Published January 28, 2011 | Version v1
Journal article

miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras

  • 1. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095 (United States)
  • 2. Dental Research Institute, University of California, Los Angeles, CA 90095 (United States)
  • 3. School of Dentistry, University of California, Los Angeles, CA 90095 (United States)
  • 4. David Geffen School of Medicine, University of California, Los Angeles, CA 90095 (United States)

Description

Research highlights: → MicroRNA-181a (miR-181a) was frequently downregulated in oral squamous cell carcinoma (OSCC). → Overexpression of miR-181a suppressed OSCC growth. → K-ras is a novel target of miR-181a. → Decreased miR-181a expression is attributed to its lower promoter activity in OSCC. -- Abstract: MicroRNAs (miRNAs) are epigenetic regulators of gene expression, and their deregulation plays an important role in human cancer, including oral squamous cell carcinoma (OSCC). Recently, we found that miRNA-181a (miR-181a) was upregulated during replicative senescence of normal human oral keratinocytes. Since senescence is considered as a tumor suppressive mechanism, we thus investigated the expression and biological role of miR-181a in OSCC. We found that miR-181a was frequently downregulated in OSCC. Ectopic expression of miR-181a suppressed proliferation and anchorage independent growth ability of OSCC. Moreover, miR-181a dramatically reduces the growth of OSCC on three dimensional organotypic raft culture. We also identified K-ras as a novel target of miR-181a. miR-181a decreased K-ras protein level as well as the luciferase activity of reporter vectors containing the 3'-untranslated region of K-ras gene. Finally, we defined a minimal regulatory region of miR-181a and found a positive correlation between its promoter activity and the level of miR-181a expression. In conclusion, miR-181a may function as an OSCC suppressor by targeting on K-ras oncogene. Thus, miR-181a should be considered for therapeutic application for OSCC.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.bbrc.2010.12.055

Additional details

Identifiers

DOI
10.1016/j.bbrc.2010.12.055;
PII
S0006-291X(10)02293-X;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
404
Journal Issue
4
Journal Page Range
p. 896-902
ISSN
0006-291X
CODEN
BBRCA9

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
45025680
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
CARCINOMAS; CELL PROLIFERATION; DEREGULATION; LUCIFERASE; ONCOGENES; PROMOTERS
Descriptors DEC
DISEASES; ENZYMES; GENES; NEOPLASMS; ORGANIC COMPOUNDS; OXIDASES; OXIDOREDUCTASES; PROTEINS

Optional Information

Copyright
Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.